Last reviewed · How we verify
Buprenorphine SL
Buprenorphine SL is a Partial mu-opioid receptor agonist Small molecule drug developed by New York State Psychiatric Institute. It is currently FDA-approved for Opioid use disorder (maintenance treatment), Opioid dependence.
Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder.
Buprenorphine SL is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It is used to treat opioid-related disorders, including drug addiction, and has been studied in clinical trials for conditions such as opioid-related disorders and substance abuse.
At a glance
| Generic name | Buprenorphine SL |
|---|---|
| Sponsor | New York State Psychiatric Institute |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Buprenorphine binds with high affinity to mu-opioid receptors in the central nervous system but produces only partial agonist effects, creating a ceiling effect that limits euphoria and overdose risk compared to full opioid agonists. This partial agonism simultaneously suppresses withdrawal symptoms and reduces illicit opioid use by decreasing cravings. The sublingual formulation allows for rapid absorption and is commonly combined with naloxone to deter intravenous misuse.
Approved indications
- Opioid use disorder (maintenance treatment)
- Opioid dependence
Common side effects
- Headache
- Constipation
- Nausea
- Insomnia
- Sweating
- Dizziness
Key clinical trials
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings (PHASE4)
- Buprenorphine for Individuals in Jail (PHASE3)
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder (PHASE4)
- Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (PHASE3)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
- EXHIT ENTRE Comparative Effectiveness Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buprenorphine SL CI brief — competitive landscape report
- Buprenorphine SL updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI
Frequently asked questions about Buprenorphine SL
What is Buprenorphine SL?
How does Buprenorphine SL work?
What is Buprenorphine SL used for?
Who makes Buprenorphine SL?
What drug class is Buprenorphine SL in?
What development phase is Buprenorphine SL in?
What are the side effects of Buprenorphine SL?
What does Buprenorphine SL target?
Related
- Drug class: All Partial mu-opioid receptor agonist drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: New York State Psychiatric Institute — full pipeline
- Therapeutic area: All drugs in Psychiatry / Addiction Medicine
- Indication: Drugs for Opioid use disorder (maintenance treatment)
- Indication: Drugs for Opioid dependence
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing